Fc-engineering for improved cancer immunotherapy
Biochemical Society Transactions · 26.08.2026 · 54 (8) · 1117-1130
DOI: 10.1042/bst20250554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 20.08.2026. Verfasst von Ella Borgman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harvard College, Cambridge, Massachusetts, U.S.A. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Protein Engineering, Immunoglobulin Fc Fragments. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rheumatology Research Foundation (RRF), HHS | National Institutes of Health (NIH), NCI NIH HHS.
Abstract (Originalsprache)
Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fcγ receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard College, Cambridge, Massachusetts, U.S.A.
- Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, U.S.A.
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, U.S.A.
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, U.S.A.
ORCID-Profile: Ella Borgman, Camille Le Gall, Hidde Ploegh, Novalia Pishesha
Förderung
- Rheumatology Research Foundation (RRF)
- HHS | National Institutes of Health (NIH)
- NCI NIH HHS
- Boston Children's Hospital (BCH)
- Breakthrough T1D (JDF)
- American Heart Association (AHA)
- Lupus Research Alliance (LRA)
- Charles H. Hood Foundation (CHF)
Zitieren
APA
Borgman, E., Le Gall, C., Ploegh, H., & Pishesha, N. (2026). Fc-engineering for improved cancer immunotherapy. Biochemical Society Transactions, 54(8), 1117-1130. https://doi.org/10.1042/bst20250554
Vancouver
Borgman E, Le Gall C, Ploegh H, Pishesha N. Fc-engineering for improved cancer immunotherapy. Biochemical Society Transactions. 2026;54(8):1117-1130. doi:10.1042/bst20250554
BibTeX
@article{Borgman2026,
author = {Borgman, Ella and Le Gall, Camille and Ploegh, Hidde and Pishesha, Novalia},
title = {Fc-engineering for improved cancer immunotherapy},
journal = {Biochemical Society Transactions},
year = {2026},
volume = {54},
number = {8},
pages = {1117--1130},
doi = {10.1042/bst20250554}
}
EUVIMED